GlassScriptPhysician profile
Thomas M Sweeney
NPI 1336138239
$2,284,166.03
in general payments reported to CMS, 2019-2025
8 companies · $39K in 2025
The $39K reported for 2025 was more than what 85% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
See the full distribution for Orthopaedic Surgery of the Spine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193K · 2020: $445K · 2021: $603K · 2022: $715K · 2023: $149K · 2024: $140K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $309K · Royalty Or License: $19K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $309,039.50 |
| Royalty Or License | $18,689.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celtic Biodevices LLC | $1,767,252.97 | 2019-2025 | Medyssey Artemis Screw System |
| Captiva Spine INC | $409,933.53 | 2019-2022 | |
| Nuvasive, INC. | $101,767.21 | 2019-2023 | Xlif |
| Globus Medical, INC. | $2,512.82 | 2024 | Xlif |
| Arthrex, INC. | $1,545.62 | 2020 | |
| Ortho Development Corporation | $904.75 | 2019-2021 | |
| Alphatec Spine, INC | $207.06 | 2019 | |
| Nexus Spine, LLC | $42.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.